Treatment choice for autoimmune diseases is continually expanding. Whilst biologic originators remain firmly established across many indications, they now face growing competition. In several markets payor pressure has led to rapid biosimilar uptake. Additionally, oral advanced therapies now regularly enter the market with the goal of occupying a pre-biologic position.
As a result, some autoimmune indications face potential treatment saturation. Despite this, clear unmet needs remain among both physicians and patients. Such challenges are driving an acute need amongst pharmaceutical companies to develop brands with a clear competition differentiation, both in clinical trial and real-world settings. Furthermore, drug developers are increasingly targeting indications with little or no advanced therapy use to date; including Hidradenitis Suppurativa, Sjogren’s and Scleroderma.
Our portfolio of autoimmune Disease Specific Programmes™ provides real-world insights and evidence in support of developmental and existing therapies across multiple (adults and paediatric) disease areas covering rheumatology, gastroenterology, dermatology and nephrology. Additionally, from this year we will be launching a new arm of autoimmune rare diseases.